SK283212B6 - Farmaceutický prostriedok pozostávajúci z kombinácie metformínu a fibrátu a jeho použitie na znižovanie hyperglykémie - Google Patents

Farmaceutický prostriedok pozostávajúci z kombinácie metformínu a fibrátu a jeho použitie na znižovanie hyperglykémie Download PDF

Info

Publication number
SK283212B6
SK283212B6 SK1156-2000A SK11562000A SK283212B6 SK 283212 B6 SK283212 B6 SK 283212B6 SK 11562000 A SK11562000 A SK 11562000A SK 283212 B6 SK283212 B6 SK 283212B6
Authority
SK
Slovakia
Prior art keywords
metformin
fibrate
combination
pharmaceutically acceptable
pharmaceutical composition
Prior art date
Application number
SK1156-2000A
Other languages
English (en)
Slovak (sk)
Other versions
SK11562000A3 (sk
Inventor
Yves Bonhomme
Philippe Briet
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Publication of SK11562000A3 publication Critical patent/SK11562000A3/sk
Publication of SK283212B6 publication Critical patent/SK283212B6/sk

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
SK1156-2000A 1998-02-12 1999-01-30 Farmaceutický prostriedok pozostávajúci z kombinácie metformínu a fibrátu a jeho použitie na znižovanie hyperglykémie SK283212B6 (sk)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9801709A FR2774591B1 (fr) 1998-02-12 1998-02-12 Composition pharmaceutique comprenant l'association metformine et fibrate et son utilisation pour la preparation de medicaments destines a reduire l'hyperglycemie
PCT/EP1999/000614 WO1999040904A2 (en) 1998-02-12 1999-01-30 Pharmaceutical composition comprising a combination of metformin and fibrate, and its use for the treatment of hyperglycemia

Publications (2)

Publication Number Publication Date
SK11562000A3 SK11562000A3 (sk) 2000-12-11
SK283212B6 true SK283212B6 (sk) 2003-03-04

Family

ID=9522912

Family Applications (1)

Application Number Title Priority Date Filing Date
SK1156-2000A SK283212B6 (sk) 1998-02-12 1999-01-30 Farmaceutický prostriedok pozostávajúci z kombinácie metformínu a fibrátu a jeho použitie na znižovanie hyperglykémie

Country Status (28)

Country Link
US (1) US6372790B1 (de)
EP (1) EP1054665B1 (de)
JP (1) JP4767411B2 (de)
KR (1) KR100567608B1 (de)
CN (1) CN1151785C (de)
AR (1) AR018286A1 (de)
AT (1) ATE204754T1 (de)
AU (1) AU746821B2 (de)
BR (1) BRPI9907866B8 (de)
CA (1) CA2320039C (de)
CZ (1) CZ290101B6 (de)
DE (1) DE69900249T2 (de)
DK (1) DK1054665T3 (de)
ES (1) ES2162517T3 (de)
FR (1) FR2774591B1 (de)
HK (1) HK1034913A1 (de)
HU (1) HU224619B1 (de)
ID (1) ID26254A (de)
MY (1) MY118164A (de)
NO (1) NO328314B1 (de)
PL (1) PL196874B1 (de)
PT (1) PT1054665E (de)
RU (1) RU2207850C2 (de)
SK (1) SK283212B6 (de)
TW (1) TW518222B (de)
UA (1) UA70315C2 (de)
WO (1) WO1999040904A2 (de)
ZA (1) ZA991077B (de)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4278863B2 (ja) * 1997-12-08 2009-06-17 ブリストル−マイヤーズ スクイブ カンパニー メトホルミンの新規塩および方法
US6982281B1 (en) 2000-11-17 2006-01-03 Lipocine Inc Pharmaceutical compositions and dosage forms for administration of hydrophobic drugs
FR2796551B1 (fr) * 1999-07-23 2003-07-25 Lipha Nouveaux sels de metformine, leur procede d'obtention et les compositions pharmaceutiques en renfermant
FR2796940B1 (fr) * 1999-07-26 2005-04-08 Lipha Nouveaux sels de metformine, leur procede d'obtention et les compositions pharmaceutiques en renfermant
US6586438B2 (en) 1999-11-03 2003-07-01 Bristol-Myers Squibb Co. Antidiabetic formulation and method
EP1246792B1 (de) * 2000-01-13 2014-08-13 Emisphere Technologies, Inc. Verbindungen und zusammensetzung zur abgabe von wirkstoffen
US6531158B1 (en) * 2000-08-09 2003-03-11 Impax Laboratories, Inc. Drug delivery system for enhanced bioavailability of hydrophobic active ingredients
JP4829411B2 (ja) * 2001-02-23 2011-12-07 キッセイ薬品工業株式会社 Ｃ型慢性肝炎治療剤
GB0119480D0 (en) 2001-08-09 2001-10-03 Jagotec Ag Novel compositions
US8911781B2 (en) 2002-06-17 2014-12-16 Inventia Healthcare Private Limited Process of manufacture of novel drug delivery system: multilayer tablet composition of thiazolidinedione and biguanides
EP1424070A1 (de) * 2002-11-28 2004-06-02 Fournier Laboratories Ireland Limited Zusammensetzung von einem PPAR-alpha Agonisten und Metformin zur Senkung des Serumtriglyceridspiegels
ATE411010T1 (de) 2002-12-13 2008-10-15 Jagotec Ag Topische nanopartikel-spironolacton-formulierung
FR2851734B1 (fr) * 2003-02-28 2006-06-09 Galenix Innovations Procede pour la fabrication d'une composition pharmaceutique sous la forme de comprimes contenant un fibrate et comprimes obtenus selon le procede
FR2858556B1 (fr) * 2003-08-06 2006-03-10 Galenix Innovations Composition pharmaceutique solide dispersible et/ou orodispersible non pelliculee contenant au moins le principe actif metformine, et procede de preparation
US8062664B2 (en) * 2003-11-12 2011-11-22 Abbott Laboratories Process for preparing formulations of lipid-regulating drugs
CN101897970A (zh) 2003-12-19 2010-12-01 奥加生物药业(I.P.3)有限公司 用于治疗糖尿病的组合物和方法
EP1559419A1 (de) * 2004-01-23 2005-08-03 Fournier Laboratories Ireland Limited Pharmazeutische Darreichungsformen enthaltend Metformin und ein Fibrat, sowie deren Herstellungsprozesse
JP4901218B2 (ja) * 2004-02-09 2012-03-21 あすか製薬株式会社 併用医薬
EP1591114A1 (de) * 2004-03-12 2005-11-02 Fournier Laboratories Ireland Limited Verwendung von Metformin und Orlistat zur Behandlung oder Vorbeugung von Obesität
US20060286182A1 (en) * 2005-06-21 2006-12-21 Abeille Pharmaceuticals, Inc. Synergistic cinnamon combinations and methods for enhancing insulin activity
GB0602639D0 (en) * 2006-02-09 2006-03-22 Novartis Ag Organic compounds
US20090318496A1 (en) 2006-08-04 2009-12-24 Aska Pharmaceutical Co., Ltd. Preparation containing fibrate agent and process for producing the same
CN101342164B (zh) * 2007-08-21 2011-04-20 阜新市仙鹤制药有限责任公司 苯扎贝特控释制剂及其制备方法
US11304960B2 (en) 2009-01-08 2022-04-19 Chandrashekar Giliyar Steroidal compositions
ES2344183B1 (es) * 2009-02-18 2011-06-10 Italfarmaco, S.A. Uso de agentes sensibilizantes a insulina por via vaginal.
US9339458B2 (en) * 2009-02-18 2016-05-17 Itf Research Pharma, S.L.U. Use of vaginal insulin sensitizing agents
US20180153904A1 (en) 2010-11-30 2018-06-07 Lipocine Inc. High-strength testosterone undecanoate compositions
US9358241B2 (en) 2010-11-30 2016-06-07 Lipocine Inc. High-strength testosterone undecanoate compositions
US9034858B2 (en) 2010-11-30 2015-05-19 Lipocine Inc. High-strength testosterone undecanoate compositions
US20120148675A1 (en) 2010-12-10 2012-06-14 Basawaraj Chickmath Testosterone undecanoate compositions
JP2012171911A (ja) 2011-02-22 2012-09-10 Kao Corp Ｐｐａｒ活性化剤
US9382187B2 (en) * 2012-07-10 2016-07-05 Thetis Pharmaceuticals Llc Tri-salt form of metformin
CN104684889A (zh) * 2012-07-10 2015-06-03 西蒂斯制药有限责任公司 二甲双胍的三盐形式
US8765811B2 (en) * 2012-07-10 2014-07-01 Thetis Pharmaceuticals Llc Tri-salt form of metformin
US9505709B2 (en) 2014-05-05 2016-11-29 Thetis Pharmaceuticals Llc Compositions and methods relating to ionic salts of peptides
US10166246B2 (en) 2014-05-27 2019-01-01 City Of Hope TGR5 agonist complexes for treating diabetes and cancer
US9242008B2 (en) 2014-06-18 2016-01-26 Thetis Pharmaceuticals Llc Mineral amino-acid complexes of fatty acids
MX2016016830A (es) 2014-06-18 2017-07-07 Thetis Pharmaceuticals Llc Complejos de aminoacidos minerales de agentes activos.
US9498485B2 (en) 2014-08-28 2016-11-22 Lipocine Inc. Bioavailable solid state (17-β)-hydroxy-4-androsten-3-one esters
US20170246187A1 (en) 2014-08-28 2017-08-31 Lipocine Inc. (17-ß)-3-OXOANDROST-4-EN-17-YL TRIDECANOATE COMPOSITIONS AND METHODS OF THEIR PREPARATION AND USE
FR3050112B1 (fr) * 2016-04-15 2020-09-04 Soc Civ Immobiliere Gecinq Utilisation de l'acide fenofibrique dans le traitement des maladies hepatiques
KR102437682B1 (ko) 2016-06-03 2022-08-29 테티스 파마수티컬스 엘엘씨 특화된 사전 해소 매개체의 염에 관한 조성물 및 방법
WO2018058109A1 (en) * 2016-09-26 2018-03-29 Nusirt Sciences, Inc. Compositions and methods for treating metabolic disorders
FR3056908B1 (fr) * 2016-09-30 2019-04-19 Nashpharm Sel de metformine et d'elafibranor presentant une activite duale pour le traitement de l'obesite associee a la steato-hepatite non alcoolique (nash) et a l'hypertriglyceridemie
US11559530B2 (en) 2016-11-28 2023-01-24 Lipocine Inc. Oral testosterone undecanoate therapy
GB2599950A (en) * 2020-10-16 2022-04-20 Zentiva Ks Pharmaceutical compositions with low amounts of nitrosamine impurities and methods for producing the same
WO2023119100A1 (en) * 2021-12-22 2023-06-29 Mankind Pharma Ltd. Stable pharmaceutical compositions

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2264525B1 (de) * 1974-03-22 1977-11-04 Expl Marques Brevets Et
US4080472A (en) 1974-03-22 1978-03-21 Societe D'etudes Et D'exploitation De Marques Et Brevets S.E.M.S. Metformin 2-(p-chlorophenoxy)-2-methylpropionate
DE3729209A1 (de) * 1987-09-01 1989-03-09 Boehringer Mannheim Gmbh Verwendung von bezafibrat zur behandlung von diabetes
JP3852621B2 (ja) * 1992-01-21 2006-12-06 あすか製薬株式会社 血管内皮細胞機能改善剤
WO1998005331A2 (en) * 1996-08-02 1998-02-12 Ligand Pharmaceuticals Incorporated Prevention or treatment of type 2 diabetes or cardiovascular disease with ppar modulators

Also Published As

Publication number Publication date
EP1054665A2 (de) 2000-11-29
CZ290101B6 (cs) 2002-05-15
FR2774591B1 (fr) 2000-05-05
JP4767411B2 (ja) 2011-09-07
CN1151785C (zh) 2004-06-02
NO328314B1 (no) 2010-01-25
UA70315C2 (en) 2004-10-15
SK11562000A3 (sk) 2000-12-11
ES2162517T3 (es) 2001-12-16
AU746821B2 (en) 2002-05-02
BRPI9907866B8 (pt) 2021-05-25
PL342665A1 (en) 2001-07-02
PT1054665E (pt) 2002-02-28
MY118164A (en) 2004-09-30
FR2774591A1 (fr) 1999-08-13
EP1054665B1 (de) 2001-08-29
NO20004056D0 (no) 2000-08-11
PL196874B1 (pl) 2008-02-29
KR100567608B1 (ko) 2006-04-04
ID26254A (id) 2000-12-07
RU2207850C2 (ru) 2003-07-10
DK1054665T3 (da) 2001-12-27
KR20010040925A (ko) 2001-05-15
HUP0100801A3 (en) 2001-12-28
WO1999040904A2 (en) 1999-08-19
CA2320039C (en) 2008-07-22
BR9907866A (pt) 2000-10-31
AU2923399A (en) 1999-08-30
CZ20002828A3 (cs) 2000-11-15
WO1999040904A3 (en) 1999-09-30
ATE204754T1 (de) 2001-09-15
AR018286A1 (es) 2001-11-14
DE69900249D1 (de) 2001-10-04
BRPI9907866B1 (pt) 2017-08-15
HU224619B1 (hu) 2005-11-28
US6372790B1 (en) 2002-04-16
JP2002502869A (ja) 2002-01-29
HK1034913A1 (en) 2001-11-09
CA2320039A1 (en) 1999-08-19
ZA991077B (en) 1999-08-11
CN1290160A (zh) 2001-04-04
DE69900249T2 (de) 2002-06-13
TW518222B (en) 2003-01-21
NO20004056L (no) 2000-08-11
HUP0100801A2 (hu) 2001-08-28

Similar Documents

Publication Publication Date Title
SK283212B6 (sk) Farmaceutický prostriedok pozostávajúci z kombinácie metformínu a fibrátu a jeho použitie na znižovanie hyperglykémie
EP1097710B1 (de) Kombinationspräparat zur Behandlung von nicht-Insulinabhängige Diabetes Mellitus (NIDDM)
US20010047000A1 (en) Partial fatty acid oxidation inhibitors in the treatment of congestive heart failure
SK19662000A3 (sk) ZLISOVANí DVOJVRSTVOVí PEVNí PROSTRIEDOK
US20230293495A1 (en) Pharmaceutical formulations for treating diseases mediated by kdm1a
US20070259941A1 (en) Ramipril formulation
HUE034007T2 (en) Treatment of atrial fibrillation
ES2704979T3 (es) Formulaciones galénicas de aliskiren e hidroclorotiazida
KR20130126253A (ko) 복용순응도가 향상된 서방성 당뇨병 치료용 복합제제 및 이의 제조방법
EP1769793A1 (de) Therapeutisches und präventives arzneimittel für diabetes, fettleibigkeit und arteriosklerose
US20060030623A1 (en) Agent for the treatment or prevention of diabetes, obesity or arteriosclerosis
KR20090024248A (ko) Ｃｘｃｒ2의 선택적 길항제 또는 ｃｘｃｒ1과 ｃｘｃｒ2 둘다의 선택적 길항제의 약제학적 제형 및 조성물, 및 염증성 질환을 치료하기 위한 이의 사용방법
HU207455B (en) Method for producing pharmaceutical preparations suitable for treating postischemical heart-troubles containing captoprile and in given case thrombolitic agent
MXPA00007739A (en) Pharmaceutical composition comprising a combination of metformin and fibrate, and its use for the preparation of medicines intended to reduce hyperglycaemia
RU2442585C2 (ru) Способ лечения диабета
US20040014797A1 (en) Pharmaceutical composition comprising metformin and a 5-phenoxyalkyl-2,4-thiazolidinedione-type derivative
RU2273482C2 (ru) Фармацевтическая композиция с пролонгированным высвобождением гликлазида
CN1704048A (zh) 复方羟苯磺酸钙
Velotti et al. Anesthesia in Dentistry
WO2003092726A1 (en) Combination of insulin and a thiazolidinedione derivative, and use thereof for treating diabetes

Legal Events

Date Code Title Description
MK4A Patent expired

Expiry date: 20190130